FLORHAM PARK, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, announced today that it has completed a major balance sheet restructuring resulting in the retirement of all $32.0 million of the Company's senior secured debt plus $9.6 million in associated unpaid interest. As part of this restructuring, Celularity entered into an Asset Purchase Agreement and a License ...

Company Performance - Xencor reported a quarterly loss of $0.41 per share, which is better than the Zacks Consensus Estimate of a loss of $0.78, and an improvement from a loss of $1.07 per share a year ago [1] - The quarterly report represents an earnings surprise of +47.44%, having surpassed consensus EPS estimates three times over the last four quarters [2] - The company posted revenues of $43.61 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 116.92%, compared to revenues of $16.96 million a year ago [3] Stock Performance - Xencor shares have declined approximately 65.4% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [4] - The current consensus EPS estimate for the upcoming quarter is -$0.77 on revenues of $20.95 million, and -$3.08 on revenues of $96.4 million for the current fiscal year [8] Industry Outlook - The Medical - Drugs industry, to which Xencor belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [9] - Another company in the same industry, Plus Therapeutics, is expected to report a quarterly loss of $0.09 per share, reflecting a year-over-year change of +87.3%, with revenues projected at $1.7 million, up 32.8% from the previous year [10]

Core Viewpoint - Plus Therapeutics (PSTV) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the correlation between changes in earnings estimates and stock price movements, making it a valuable tool for investors [2][3]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to price movements based on their buying or selling activities [3]. Company Performance Indicators - The upgrade for Plus reflects an improvement in the company's underlying business, which is expected to positively influence its stock price [4]. - Over the past three months, the Zacks Consensus Estimate for Plus has increased by 78.7%, indicating a significant upward revision in earnings expectations [7]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [6]. - Plus's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9].

PitchBook Data, Inc. Nizar Tarhuni Executive Vice President of Research and Market Intelligence Paul Condra Global Head of Private Markets Research James Ulan Director of Emerging Technology Research Institutional Research Group Analysis Kazi Helal, Ph.D. Senior Research Analyst, Biotech and Pharma Data Sara Good Data Analyst pbinstitutionalresearch@pitchbook.com Publishing Designed by Jenna O'Malley Published on May 29, 2025 Contents | Key takeaways | 1 | | --- | --- | | Introduction: Biotech VC fund ecosy ...